Abstract
Non-small cell lung cancer treatment has known remarkable progress these past few years with the rise of immunotherapy, which place is increasingly expanding among the therapeutic arsenal of these cancers. More and more patients benefit from such treatments, and concomitant or sequential combinations with radiation therapy become common at all stages of the disease.Despite theorical and pre-clinical seducing data concerning a possible synergistic effect of the association, the question of clinical relevance remained open, with few evidence available on effectiveness and possible supra-additive toxicity especially pulmonary.In this article, we will review the theoretical and pre-clinical basis of the association, then we will discuss successively the available data on effectiveness and toxicity, for all stages of the disease.© 2019 SPLF. Published by Elsevier Masson SAS. All rights reserved.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
